May 12, 2023
Takeda Pharmaceutical’s group revenue crossed the 4-trillion-yen mark for the first time in FY2022, with a currency tailwind and the growth of Entyvio (vedolizumab) and other core products offsetting a pullback from a diabetes divestiture gain booked in the prior...read more